ARS Pharmaceuticals (NASDAQ:SPRY) Earns “Outperform” Rating from William Blair
ARS Pharmaceuticals (NASDAQ:SPRY – Get Free Report)‘s stock had its “outperform” rating reiterated by analysts at William Blair in a research note issued to investors on Monday,RTT News reports. Several other analysts have also recently weighed in on the stock. Leerink Partners raised their price objective on shares of ARS Pharmaceuticals from $26.00 to $27.00 […]
ARS Pharmaceuticals (NASDAQ:SPRY – Get Free Report)‘s stock had its “outperform” rating reiterated by analysts at William Blair in a research note issued to investors on Monday,RTT News reports. Several other analysts have also recently weighed in on the stock. Leerink Partners raised their price objective on shares of ARS Pharmaceuticals from $26.00 to $27.00 […]
